Hoestbruistabletten Acetylcysteïne Da (Acetylcysteine)

Hoestbruistabletten Acetylcysteïne Da is indicated for several respiratory disorders where mucus clearance is impaired.

• Acute bronchitis with productive cough
• Chronic bronchitis
• Chronic obstructive pulmonary disease (COPD)
• Cystic fibrosis as an adjunct mucolytic
• Situations with thick, tenacious sputum such as after surgery or in smokers

• Acetylcysteine acts as a mucolytic by cleaving the disulfide bonds that link mucin glycoprotein chains within airway secretions. This reduction in cross‑linking decreases the viscosity and elasticity of mucus, allowing it to become less tenacious and more easily transported by ciliary action or coughing. The molecule also provides cysteine, a precursor for glutathione, which can contribute to antioxidant effects in the respiratory epithelium.

Adverse reactions to Hoestbruistabletten Acetylcysteïne Da are generally mild, but rare serious events have been reported.

Common

• Nausea or upset stomach
• Vomiting
• Mild abdominal discomfort
• Transient rash or itching

Serious

• Anaphylactic reaction with breathing difficulty
• Severe skin reactions such as Stevens‑Johnson syndrome

Before using Hoestbruistabletten Acetylcysteïne Da, consider the following precautions:

• Assess for known hypersensitivity to acetylcysteine or any tablet excipients.
• Use cautiously in patients with asthma, as bronchospasm may be precipitated.
• Monitor liver function in individuals with pre‑existing hepatic impairment.
• Adjust use in patients with renal insufficiency, especially if high‑dose regimens are considered.
• Avoid in patients with active peptic ulcer disease if gastrointestinal irritation is a concern.
• Discuss use during pregnancy or lactation with a healthcare professional, as safety data are limited.

Hoestbruistabletten Acetylcysteïne Da may interact with other medicines. Review the following categories:

Avoid

• Nitrofurantoin, because acetylcysteine can reduce its urinary concentration.
• Activated charcoal, which may adsorb the drug and decrease its absorption.

Use with caution

• Antihistamines or other agents that may mask allergic reactions.
• Bronchodilators, as concurrent use may increase the risk of bronchospasm.
• Anticoagulants (e.g., warfarin), since changes in plasma protein binding could affect clotting parameters.
• Other mucolytics, to avoid excessive thinning of secretions.
• Medications metabolized by the liver, as acetylcysteine may influence hepatic enzyme activity.